Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal – Endpoints News
|
Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal
Endpoints News With one gene therapy for hemophilia B well along the way in the clinic at Spark Therapeutics, pharma giant Pfizer $PFE is now extending its interest in the field with a pact with Sangamo on a new gene therapy for hemophilia A. The exclusive worldwide … Sangamo Biosciences (SGMO), Pfizer (PFE) Enter Pact on Hemophilia A Gene Therapy |
